Achieve Life Sciences (NASDAQ:ACHV) Stock Price Down 6.8% – Should You Sell?

Posted by Brian Himes on Nov 2nd, 2026

Achieve Life Sciences, Inc. (NASDAQ:ACHV – Get Free Report)’s stock price was down 6.8% during mid-day trading on Monday. The company traded as low as $6.44 and last traded at $6.3650. 475,831 shares changed hands during mid-day trading, a decline of 65% from the average session volume of 1,352,472 shares. The stock had previously closed at $6.83.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on ACHV shares. Wall Street Zen cut Achieve Life Sciences from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 15th. Stifel Nicolaus set a $18.00 target price on shares of Achieve Life Sciences and gave the stock a “buy” rating in a report on Tuesday, September 29th. Morgan Stanley assumed coverage on shares of Achieve Life Sciences in a research report on Thursday, August 13th. They set an “overweight” rating and a $13.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Achieve Life Sciences in a report on Wednesday, August 19th. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $18.00 price objective on shares of Achieve Life Sciences in a research note on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Achieve Life Sciences has a consensus rating of “Buy” and an average target price of $15.50.

Get Our Latest Stock Analysis on Achieve Life Sciences

Achieve Life Sciences Stock Down 5.6%

The company has a 50-day moving average of $7.45 and a 200-day moving average of $5.65. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 0.87. The company has a market capitalization of $663.19 million, a price-to-earnings ratio of -4.16 and a beta of 2.42.

Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.64). On average, equities analysts predict that Achieve Life Sciences, Inc. will post -0.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Richard Stewart sold 20,626 shares of Achieve Life Sciences stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $8.49, for a total value of $175,114.74. Following the completion of the sale, the director directly owned 208,249 shares in the company, valued at $1,768,034.01. This trade represents a 9.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Frazier Life Sciences Management L.P. purchased a new position in Achieve Life Sciences in the 2nd quarter worth $49,725,000. venBio Partners LLC purchased a new stake in Achieve Life Sciences during the 2nd quarter valued at about $38,623,122. Bank of America Corp DE purchased a new stake in Achieve Life Sciences during the 2nd quarter valued at about $1,209,000. Spruce Street Capital LP purchased a new stake in Achieve Life Sciences during the 2nd quarter valued at about $4,810,240. Finally, Wellington Management Group LLP acquired a new position in shares of Achieve Life Sciences in the second quarter valued at about $9,318,000. Hedge funds and other institutional investors own 33.52% of the company’s stock.

About Achieve Life Sciences

(Get Free Report)

Achieve Life Sciences, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cytisinicline, a therapy designed to help adults quit smoking and overcome nicotine addiction. Cytisinicline is an oral, plant-based small molecule that partially activates nicotinic acetylcholine receptors, with the goal of reducing nicotine cravings and withdrawal symptoms.

The company has evaluated cytisinicline in clinical studies involving adults who smoke cigarettes, including trials assessing smoking cessation and cessation of electronic cigarette use.